Study of SX-682 with atezolizumab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination (SX-682 plus atezolizumab) for people with advanced non-small cell lung cancer that has grown after standard treatments like immunotherapy and chemotherapy. It aims to see if the combination can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced or recurrent non-small cell lung cancer that has spread or cannot be removed by surgery.
- Your cancer must have gotten worse after at least 6 weeks of treatment with an anti-PD-1 or anti-PD-L1 drug and after prior platinum chemotherapy.
- You must have at least one tumor that can be measured on scans.
- You must be willing to provide a tumor sample from before treatment (or have a biopsy if needed) and another sample during treatment.
- Your overall health must be good enough for daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial studies a two-drug treatment (cabozantinib plus atezolizumab) for people with advanced or metastatic non-small cell lung cancer (NSCLC). It may help control the cancer and shrink tumors, especially for patients whose tumor tests show low PD-L1 and who fit the trial’s prior-treatment rules.
This trial combines two drugs—docetaxel (a standard chemotherapy) and SX-682 (an experimental drug that may help the immune system fight cancer)—to see if they work better together for people with certain advanced cancers that have spread or come back. It is for patients with head and neck squamous cell cancer, salivary gland cancer, or advanced prostate cancer.
Hear when a new Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.